Anti-Thyroid Antibodies and TSH as Potential Markers of Thyroid Carcinoma and Aggressive Behavior in Patients with Indeterminate Fine-Needle Aspiration Cytology
Indeterminate fine-needle aspiration cytology (FNAC) imposes challenges in the management of thyroid nodules. This study aimed to examine whether preoperative anti-thyroid antibodies (Abs) and TSH are indicators of thyroid malignancy and aggressive behavior in patients with indeterminate FNAC.
This was a retrospective study of thyroidectomy patients from 2008 to 2016. We analyzed Abs and TSH levels, FNAC, and histopathology. Serum antibody levels were categorized as ‘Undetectable’, ‘In-range’ if detectable but within normal range, and ‘Elevated’ if above upper limit of normal. ‘Detectable’ levels referred to ‘In-range’ and ‘Elevated’ combined.
There were 531 patients included. Of 402 patients with preoperative FNAC, 104 (25.9%) had indeterminate cytology (Bethesda III–V). Of these, 39 (37.5%) were malignant and 65 (62.5%) benign on histopathology. In the setting of indeterminate FNAC, an increased risk of malignancy was associated with ‘Elevated’ thyroglobulin antibodies (TgAb) (OR 7.25, 95% CI 1.13–77.15, P = 0.01) and ‘Elevated’ thyroid peroxidase antibodies (TPOAb) (OR 6.79, 95% CI 1.23–45.88, P = 0.008). Similarly, while still ‘In-range’, TSH ≥ 1 mIU/L was associated with an increased risk of malignancy (OR 3.23, 95% CI 1.14–9.33, P = 0.01). In all patients with malignancy, the mean tumor size was 8 mm larger in those with TSH ≥ 1 mIU/L (P = 0.03); furthermore, in PTC patients, ‘Detectable’ TgAb conferred a 4 × risk of lymph node metastasis (95% CI 1.03–13.77, P = 0.02).
In this cohort, in indeterminate FNAC patients, Abs and TSH were associated with an increased risk of malignancy. Additionally, TgAb and TSH were potential markers of aggressive biology. As such, they may be diagnostic and prognostic adjuncts.
We would like to acknowledge all the surgeons who have contributed cases to the Monash University Endocrine Surgery Unit (MUESU) database.
No grants or funding received for this project.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Study approved by Alfred Health Human Research Ethics Committee (Project No: 185/19).
- 1.Parsa AA, Gharib H (2018) Chapter 1, Epidemiology of thyroid nodules. In: Gharib H (ed) Thyroid nodules - diagnosis and management. Humana Press, Cham, p 7Google Scholar
- 2.Haugen BR, Alexander EK, Bible KC et al (2016) 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1):1–133CrossRefGoogle Scholar
- 11.Hu N, Li ZM, Liu JF et al (2016) An overall and dose-response meta-analysis for thyrotropin and thyroid cancer risk by histological type. Oncotarget 7(30):47750–47759Google Scholar
- 20.Matesa-Anic D, Matesa N, Dabelic N et al (2009) Coexistence of papillary carcinoma and Hashimoto's thyroiditis. Acta Clin Croat 48(1):9–12Google Scholar
- 33.Song E, Oh HS, Jeon MJ et al (2019) The value of preoperative antithyroidperoxidase antibody as a novel predictor of recurrence in papillary thyroid carcinoma. Int J Cancer 144(6):1414–1420Google Scholar
- 34.Kimura H, Yamashita S, Namba H et al (1992) Interleukin-1 inhibits human thyroid carcinoma cell growth. J Clin Endocrinol Metab 75(2):596–602Google Scholar
- 41.Boi F, Minerba L, Lai ML et al (2013) Both thyroid autoimmunity and increased serum TSH are independent risk factors for malignancy in patients with thyroid nodules. J Endocrinol Invest 36(5):313–320Google Scholar